FIELD: medicine; pharmaceuticals.
SUBSTANCE: present invention relates to pharmaceutical antibody compositions. In particular, the present invention refers to a stable liquid antibody composition and to its pharmaceutical preparation and use.
EFFECT: invention is illustrated by an example of an aqueous composition of the anti-vascular endothelial growth factor (VEGF) antibody.
10 cl, 3 dwg, 11 tbl, 5 ex
Title | Year | Author | Number |
---|---|---|---|
COMPOSITIONS OF ANTI-PD-1 ANTIBODIES | 2019 |
|
RU2772781C2 |
ANTI-PD-1 ANTIBODIES | 2017 |
|
RU2752832C2 |
METHODS AND COMPOSITIONS COMPRISING PURIFIED RECOMBINANT POLYPEPTIDES | 2014 |
|
RU2671481C2 |
STABLE LIQUID PREPARATION OF ANTIBODY | 2009 |
|
RU2518278C2 |
ANTI-VEGF ANTIBODIES AND APPLICATIONS THEREOF | 2010 |
|
RU2567639C2 |
STABLE PHARMACEUTICAL PREPARATION BASED ON THE PD-1 ANTIBODY AND ITS USE IN MEDICINE | 2016 |
|
RU2731418C2 |
PHARMACEUTICAL COMPOSITION OF THE FUSION PROTEIN OF THE TRANSFORMING GROWTH FACTOR BETA RECEPTOR AND ITS APPLICATION | 2019 |
|
RU2791683C2 |
METHODS AND COMPOSITIONS INCLUDING PURIFIED RECOMBINANT POLYPEPTIDES | 2014 |
|
RU2793783C1 |
BISPECIFIC ANTIBODIES | 2011 |
|
RU2573588C2 |
ANTIBODIES TO PD-1 AND METHODS OF THEIR APPLICATION | 2015 |
|
RU2701797C2 |
Authors
Dates
2019-09-06—Published
2016-01-20—Filed